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Infant mortalityBackground: Respiratory syncytial virus (RSV) infection is an important cause of infant mortality. Here,
we estimated the potential impact of maternal vaccination against RSV on life-threatening RSV infection
in infants.
Methods: We developed a mathematical model for maternal vaccine-induced antibody dynamics and
used characteristics of a maternal RSV vaccine currently in phase 3 of clinical development. The model
was applied to data from two cohorts of children younger than 12 months with RSV-related paediatric
intensive care unit (PICU) admission in the United Kingdom (n = 370) and the Netherlands (n = 167),
and a cohort of 211 children younger than 12 months with RSV-related in-hospital death from 20 coun-
tries worldwide.
Results: Our model predicted that, depending on vaccine efficiency, maternal vaccination at 30 weeks’
gestational age could have prevented 62–75% of RSV-related PICU admissions in the United Kingdom
and 76–87% in the Netherlands. For the global mortality cohort, the model predicted that maternal vac-
cination could have prevented 29–48% of RSV-related in-hospital deaths. Preterm children and children
with comorbidities were predicted to benefit less than (healthy) term children.
Conclusions: Maternal vaccination against RSV may substantially decrease life-threatening RSV infections
in infants.
 2018 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Respiratory syncytial virus infection (RSV) is an important cause
of morbidity and mortality in young children [1,2]. Globally, it is
estimated that 48,000–74,500 children aged younger than five
years died in-hospital with RSV-related lower respiratory tract
infection in 2015 [2]. About 99% of RSV-related childhood mortal-
ity occurs in developing countries [2]. Most RSV-related mortalityoccurs during the first year of life [3–6]. In our recent global case
series study of 358 children with RSV-related in-hospital death,
median age at death varied from 4 to 7 months depending on
income region (upper middle-income vs. high-income countries,
respectively) [6]. Preterm children and children with comorbidities
such as congenital heart disease or chronic lung disease are at
increased risk for severe RSV infection or even fatal RSV infection
[7–10].
Maternal vaccination is currently being considered for RSV pre-
vention in young children [11]. Maternal vaccination will only pro-
vide temporary protection due to an age-dependent decrease of
maternally-acquired protective antibodies after birth [12,13]. For
example, serological studies from Bangladesh and Kenya reported
maternally-acquired protective antibodies against RSV to be present
only up to four months after birth [14–16]. Similarly, maternal
4694 N.M. Scheltema et al. / Vaccine 36 (2018) 4693–4700vaccination against influenza and pertussis provides protection dur-
ing the first two to three months of life [12,17]. As transplacental
antibody transfer becomes efficient only from the third trimester
of pregnancy onward, maternal vaccination may provide limited
protection for preterm infants [18–20]. To date, the potential impact
of amaternalRSVvaccineonRSV-relatedmortality inyoungchildren
is unknown. In this observational, retrospective study,wedeveloped
a mathematical model for maternal vaccine-induced antibody
dynamics, taking into account transplacental antibody transfer rates
and antibody decline after birth [15,18,21–24]. We applied this
model to data from two retrospective cohorts of children with
RSV-related paediatric intensive care unit (PICU) admission and a
previously published cohort of children with RSV-related in-
hospital death [6] and predicted the percentage of life-threatening
RSV infections potentially prevented by maternal vaccination.
2. Methods
To predict the percentage of life-threatening RSV infections
potentially prevented by maternal vaccination we developed a
mathematical model for maternal vaccine-induced antibody
dynamics, taking into account transplacental transfer rates of pro-
tective antibodies during pregnancy and antibody decline in new-
born children.
2.1. Maternal vaccine-induced antibodies
Vaccination of pregnant women against RSV infection induces
an increase in maternal anti-RSV antibodies. For simplicity, mater-
nal vaccine-induced RSV-specific antibody levels were modelled as
an exponential increase between day 7 and day 21 post-
vaccination, and were assumed to stay constant afterward
[15,21,22]. We hence modelled maternal vaccine-induced RSV-
specific antibody levels (am in lg/ml) as follows (Fig. 1A):
if t < 7; am tð Þ ¼ am0
if 7  t  21; am tð Þ ¼ am0 e t7ð Þ log fð Þ=14
if t > 21; am tð Þ ¼ am0 f
where t is the time in days since vaccination, am0 the natural level of
maternal RSV-specific antibodies in lg/ml, and f the vaccine-
induced fold increase in maternal RSV-specific antibodies (later
referred to as vaccine efficiency).
2.2. Transfer of maternal antibodies
During pregnancy, maternal immunoglobulin G (IgG) antibod-
ies are transferred to the foetus by transplacental transport.
Transplacental transfer is thought to increase during pregnancy
to become most efficient during the third trimester, and at term
foetal IgG concentrations typically even exceed maternal IgG levels
[18–20,25]. Based on published data on maternal and foetal IgG
antibody levels at different time points during pregnancy (Section 5
and Fig. 3 (IgG1) of Palmeira et al. [26] which are based on Fig. 2 of
Malek et al. [18]), we chose to model maternal IgG antibody trans-
fer with an exponential function, as it gave the best description of
the experimental data [18]. The parameters of this function were
estimated using the function lm in R software (version 3.3.2) after
a log-transformation of the data and the best fit of this model to
the experimental data was found for:
r tð Þ ¼ e4:97þ0:13t
where r is the foetus-to-mother IgG transfer ratio and t is time in
days since the beginning of pregnancy (Fig. 1B).2.3. Foetal antibody levels after birth
We assumed that maternally-derived RSV-specific antibody
levels in umbilical cord blood at birth (acb in lg/ml) can be calcu-
lated directly from the RSV-specific antibody levels in the mother
and the foetus-to-mother IgG transfer ratio at time tb, the gesta-
tional age (i.e. time of birth) in days, using the following function:
acb tbð Þ ¼ am tbð Þ:rðtbÞ
After birth, maternally-acquired RSV-specific antibody levels in
the new-born were assumed to decrease with a half-life t1/2. The
RSV-specific antibody levels of new-born children (ac in lg/ml)
can therefore be described as follows (Fig. 1C):
ac tð Þ ¼ acb tbð Þ 12
 t=t1=2
where t is the age of the new-born child in days after birth.
2.4. Model parameterization
Similar antibody dynamics for maternal vaccine-induced RSV-
specific IgG and palivizumab competing antibody (PCA) have been
reported [21,27] and as more data are available for PCA we decided
to parameterize our model on PCA. A natural PCA level am0 of 33
lg/ml was used based on the phase-2 trial studying the safety
and immunogenicity of a recombinant RSV fusion protein nanopar-
ticle vaccine (RSV F vaccine) candidate in non-pregnant women of
childbearing age [21]. PCA levels after vaccination against RSV have
been reported to be 6.9–7.9-fold higher than the natural PCA level,
depending on vaccine dosing [21]. Based on these values, we con-
sidered two vaccine efficiencies (f) of 5 and 10 in our simulations.
RSV-specific antibody half-life after birth was reported to be 41
days by maternal RSV F vaccine manufacturers [23], which is in
close agreement with reported values of 36–38 days in clinical
studies measuring cord blood and infant maternally-acquired
RSV-specific antibody levels [15,28]. A child PCA level of 40 lg/
ml was considered as the protective threshold against life-
threatening RSV infection [24,29,30].
2.5. Study population
We applied our model to three independent, retrospective
cohorts of patients. Anonymised secondary patient data were
obtained through retrospective review of medical records. The first
and second cohort consisted of children aged younger than 12
months with community-acquired RSV infection admitted to the
PICU for mechanical ventilation, who all survived. The first cohort
consisted of 370 children admitted to a PICU in the United King-
dom (UK) between 2002 and 2014 and the second cohort consisted
of 167 children admitted to two PICUs in the Netherlands between
2008 and 2015. None of the children had received palivizumab
during infancy. In the third cohort, children were selected from a
retrospective case series study describing global, in-hospital,
RSV-related mortality in 358 children aged younger than five years
[6]. All children aged younger than 12 months with available data
for prematurity were included. This resulted in a study population
of 211 children with RSV-related in-hospital death from 20 coun-
tries. In the second and third cohort, when the exact gestational
age was missing (i.e. for 60 term children in the Dutch PICU cohort
and for 19 preterm and 85 term children in the mortality cohort) it
was imputed to 34 or 40 weeks of gestation for preterm or term
children respectively, based on median values of children with
complete gestational age data.
For each cohort, we defined the following subgroups:
children with comorbidities, healthy term children (born without
Fig. 1. Antibody levels after maternal vaccination in mother and child. (A) Vaccine-induced maternal antibody levels for maternal vaccination at 30 weeks’ gestational age
(WGA). (B) Transplacental antibody transfer during pregnancy. (C) Maternally-acquired antibody levels after birth for maternal vaccination at 30 WGA for a term child (born
at 40 WGA) and a preterm child (born at 34 WGA).
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preterm children (born without comorbidities, earlier than 37
weeks’ gestational age). For the global mortality cohort, countries
were categorized as (i) high income, (ii) upper middle income,
and (iii) lowermiddle or low income, on the basis of theWorld Bank
classifications for 2016 [31].2.6. Prediction of life-threatening RSV infections prevented by
maternal vaccination
To predict the percentage of children with life-threatening RSV
infection that could be prevented by maternal vaccination, we
assumed that all mothers were vaccinated during pregnancy and
used gestational age and age at RSV-related outcome (PICU admis-
sion or death). The general recommendation for maternal vaccina-
tion against pertussis is to vaccinate during the late-second or
early-third trimester of pregnancy [32,33], while future maternal
RSV vaccination is suggested during the third trimester [23].
Therefore, to evaluate the effect of timing of maternal vaccination,
we first considered a large window for maternal vaccination
between 22 and 40 weeks of gestation and then reported results
on maternal vaccination at 30 weeks of gestation as a reflection
of the recommendation to vaccinate during the early-third trime-
ster of pregnancy.
For each child, we predicted the antibody level at birth taking
into account timing of maternal vaccination, vaccine efficiency
and gestational age at birth and then modelled antibody level
decline until the observed time of RSV-related outcome (age atPICU admission or death). We considered that a RSV-related out-
come would be prevented (or at least postponed) if the simulated
vaccine-derived protective antibody level was above the protective
threshold at the time of outcome.3. Results
3.1. Study population
Among the 370 children with RSV-related PICU admission for
mechanical ventilation in the United Kingdom, 107 (29%) were
born preterm and median age at the time of PICU admission was
49 days (InterQuartileRange (IQR) 30–88) (Table 1). In the Dutch
cohort of children admitted to the PICU, 35 (21%) were born pre-
term and median age at the time of PICU admission was 38 days
(IQR 27–63). The prevalence of comorbidity was reported to be
28% (n = 102) for the PICU cohort from the United Kingdom and
11% (n = 19) for the PICU cohort from the Netherlands.
Among the 211 children with global, RSV-related in-hospital
death, 51 (24%) were born preterm and median age at the time
of RSV-related death was 4 months (IQR 2–7). In the global mortal-
ity cohort, comorbidities were reported for 103 (49%) children, and
103 (49%) children were from high-income countries (Table 1).
Median length of stay in hospital for children with RSV-related
in-hospital death was 9 days (IQR 4–22, n = 205). For each cohort,
the distributions for gestational age (GA) and age at RSV-related
outcome (PICU admission or death) are shown in Fig. 2.
Table 1
Clinical characteristics in children with RSV-related PICU admission or in-hospital death.
PICU cohort from the United Kingdom PICU cohort from the Netherlands Global mortality cohort
N 370 167 211
Male sex 222 (60) 94 (56) 116 (55)
Age at RSV-related outcomea (days) 49 [30–88] 38 [27–63] 122 [61–213]
Prematurity (<37 WGA) 107 (29) 35 (21) 51 (24)
Gestational age (weeks) 40 [36–40] 40 [37–40] 40 [37–40]
Comorbidity status
Comorbidity 102 (28) 19 (11) 103 (49)
Healthy and term 182 (49) 117 (70) 78 (37)
Healthy and preterm 86 (23) 31 (19) 30 (14)
Country of origin
Low-income or lower middle-income 60 (28)
Upper middle-income 48 (23)
High-income 370 (100) 167 (100) 103 (49)
Data are n (%) or median [IQR]. RSV = respiratory syncytial virus. PICU = paediatric intensive care unit.
a PICU admission or death.
Fig. 2. Distribution of gestational age and age at outcome and the predicted percentage of children with life-threatening RSV infection prevented by maternal vaccination for
each cohort. Gestational age in weeks (left), age at outcome in weeks (middle) and predicted percentage of prevented cases are plotted for (A) PICU cohort from the United
Kingdom (n = 370), (B) PICU cohort from the Netherlands (n = 167) and (C) Global mortality cohort (n = 211). The predicted percentages of prevented cases were calculated for
two vaccine efficiencies (f = 10 solid line and f = 5 dashed line).
4696 N.M. Scheltema et al. / Vaccine 36 (2018) 4693–47003.2. Percentage of life-threatening RSV infections prevented by
maternal vaccination
We applied the mathematical model for maternal vaccine-
induced antibody levels (see Section 2) to individual patient data(gestational age and age at RSV-related outcome) from the three
study cohorts. We hence predicted the percentage of outcomes
that could have been prevented (or at least postponed) if mothers
had been vaccinated between 22 and 40 weeks of gestation for two
vaccine efficiencies (f = 5 and 10, see Section 2).
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would be highest if the maternal vaccine would be administered
between 22 and approximately 30 weeks’ GA and would start to
decrease for maternal vaccination after 30 weeks’ GA as a result
of the time required to reach maternal antibody peak levels
(Fig. 2). The highest predicted percentage prevented was lower
than 100% (80% in the UK cohort and 88% in the Dutch cohort with
a vaccine efficiency of 10) and observed for maternal vaccination
during the second trimester (between 22 and 26 weeks’ GA). This
resulted from the prevalence of prematurity and from age at PICU
admission at which antibodies had already declined below the pro-
tective threshold. In the global mortality cohort, maternal vaccina-
tion during the second trimester would have prevented even fewer
cases (maximum of 50% for a vaccine efficiency of 10). This lower
percentage resulted from the higher age of children at RSV-
related death (compared to the average age at PICU admission in
the other two cohorts), leading to a larger proportion of RSV-
related deaths occurring after antibody levels had already declined
below the protective threshold. Therefore, vaccine efficiency had a
larger impact on the percentage of cases prevented for the global
mortality cohort than for the PICU cohorts.Fig. 3. Distribution of gestational age and age at outcome and the predicted percentage o
each cohort stratified by prematurity status. Gestational age in weeks (left), age at outcom
PICU cohort from the United Kingdom (Term n = 263, Preterm n = 107), (B) PICU cohort f
(Term n = 160, Preterm n = 51). Term children are in orange and Preterm in blue. The pred
= 10 solid line and f = 5 dashed line).According to our model, maternal vaccination at 30 weeks’ GA
would prevent at least 62% of RSV-related PICU admissions (62–
75% in the United Kingdom and 76–87% in the Netherlands) and
29–48% of RSV-related in-hospital deaths, depending on vaccine
efficiency (Fig. 2).3.3. Impact of maternal vaccination on high-risk populations
We performed subgroup analyses to study the potential impact
of maternal vaccination on high-risk populations such as preterm
children, children with comorbidities and children from lower
income regions. In preterm children, median age at the time of PICU
admission was 53 days (IQR 32–78 and 37–80 for the United King-
dom and Netherlands respectively) and median age at the time of
RSV-related in-hospital death was 122 days (IQR 61–183) (Supple-
mental Table 1). The model predicted that maternal vaccination,
even if administered during the second trimester (i.e. 22–26 weeks’
GA), would prevent a smaller percentage of preterm than term chil-
dren in each cohort (Fig. 3). This is a direct consequence of the
reduced transplacental antibody transfer relative to the time of
birth for preterm children compared to term children. For pretermf children with life-threatening RSV infection prevented by maternal vaccination for
e in weeks (middle) and predicted percentage of prevented cases are plotted for (A)
rom the Netherlands (Term n = 132, Preterm n = 35) and (C) Global mortality cohort
icted percentages of prevented cases were calculated for two vaccine efficiencies (f
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vented 36–51% of RSV-related PICU admissions in the United King-
dom (vs. 73–85% in term children), 46–71% in the Netherlands (vs.
84–91% in term children), and 12–28% of RSV-related in-hospital
deaths (vs. 35–54% in term children). Later vaccination would fur-
ther decrease the percentage of prevented cases among preterm
children.
Children with comorbidities tended to be older at the time of
RSV-related PICU admission than healthy term children, whereas
age at the time of RSV-related in-hospital death was similar for
children with comorbidities and healthy term children (Supple-
mental Table 1). We found that children with comorbidities would
benefit less from maternal vaccination than healthy term children
regardless of the timing of maternal vaccination (Fig. 4). For the
PICU cohort from the United Kingdom, maternal vaccination at
30 weeks’ GA would have prevented PICU admission in 46–61%
of children with comorbidities (53–68% in the Dutch cohort) com-
pared to 81–91% of healthy term children (87–92% in the Dutch
cohort). For the global mortality cohort, maternal vaccination at
30 weeks’ GA would have prevented RSV-related in-hospital deathFig. 4. Distribution of gestational age and age at outcome and the predicted percentage o
each cohort stratified by comorbidity status. Gestational age in weeks (left), age at outcom
for (A) PICU cohort from the United Kingdom (Healthy term n = 182; Healthy preterm n =
117; Healthy preterm n = 31; Comorbidity n = 19) and (C) Global mortality cohort (Health
are in orange, Healthy preterm in blue and Children with comorbidities in green. The pred
= 10 solid line and f = 5 dashed line).in 26–43% of children with comorbidities compared to 40–59% of
healthy term children.
In children with RSV-related death from lower income regions
(28% of the global mortality cohort), the predicted percentage of
prevented in-hospital deaths was 30–50% for maternal vaccination
at 30 weeks’ GA and similar to that in children from other income
regions (data not shown).
4. Discussion
We have developed a mathematical model to predict the per-
centage of children with life-threatening RSV infection during the
first year of life that may be prevented by maternal vaccination.
The model was calibrated using vaccine characteristics of a mater-
nal RSV vaccine currently in phase 3 of clinical development and
was applied to individual patient data for RSV-related PICU admis-
sion and death. The model predicts that maternal vaccination
against RSV could substantially decrease life-threatening RSV
infections in infants. Preterm children and children with comor-
bidities, those at increased risk for severe RSV, were predicted tof children with life-threatening RSV infection prevented by maternal vaccination for
e in weeks (middle) and predicted percentage of prevented cases (right) are plotted
86; Comorbidity n = 102), (B) PICU cohort from the Netherlands (Healthy term n =
y term n = 78; Healthy preterm n = 30; Comorbidity n = 103). Healthy term children
icted percentages of prevented cases were calculated for two vaccine efficiencies (f
N.M. Scheltema et al. / Vaccine 36 (2018) 4693–4700 4699benefit less from a maternal RSV vaccine than term and healthy
children.
We assumed in the model that transplacental maternal anti-
body transfer increases during pregnancy and becomes most effi-
cient during the third trimester and at term, as described by
Malek et al. [18]. This assumption is in agreement with previous
studies on transplacental transfer in preterm infants for other
pathogens [19], and with a study examining the effectiveness of
maternal pertussis vaccination in England, which observed limited
benefit of maternal vaccination for preterm compared to term chil-
dren [34]. In contrast, a recent study describing maternal RSV anti-
body levels in comparison to cord blood levels in 26 preterm
infants found similar antibody levels in preterm and term children
[25], suggesting that transplacental antibody transfer may already
be efficient before the third trimester. Given the increased risk for
severe RSV infection in preterm children and the relatively high
prevalence of prematurity in lower income regions [35], where
most RSV-related childhood mortality occurs [2], having a better
knowledge of transplacental antibody transfer is essential to
improve the prediction of the impact of maternal vaccination.
A strength of our study was the use of characteristics of a
maternal RSV vaccine currently in development and of patient data
from three independent cohorts. We were able to predict the per-
centage of prevented (or at least postponed) cases for the overall
study population and for subgroups more at risk for life-
threatening RSV infection, such as preterm children or children
with comorbidities. This model was developed to study the impact
of a specific maternal RSV vaccine, but may be used for other
maternal vaccines by calibrating for specific vaccine
characteristics.
Although we have based our model on current biological
knowledge, some of the assumptions need further discussion. We
did not incorporate RSV protective antibodies acquired by natural
RSV infection during pregnancy or vaccine-induced protective
antibodies in breastmilk. These factors may influence the antibody
level in children and, therefore, protection against RSV. In addition,
we did not incorporate vaccine coverage, RSV transmission pat-
terns, risk of RSV-related disease or disease severity. A more clas-
sical approach such as the compartment model recently
published by Hogan et al. [36] in combination with our approach
would provide more insights into vaccine effectiveness at a popu-
lation level. We applied the model to three cohorts of children with
life-threatening RSV infection which has introduced selection bias.
For example, high-risk groups, such as preterm children, likely
have been overrepresented given their increased risk for severe
RSV infection, whereas the exclusion of children who had received
palivizumab prophylaxis may have resulted in underrepresenta-
tion of children with severe prematurity. Imputation of missing
gestational age data and the inclusion of preterm children (20%)
in the subgroup of children with comorbidities may also have
influenced our results. The percentage of cases prevented, as pre-
dicted by our model, should therefore not be directly extrapolated
to the general population. In addition, results may not be general-
izable to lower income regions as the majority of children in our
study were from high-income countries.
Several model assumptions may have resulted in an overesti-
mation of the impact of maternal vaccination on life-
threatening RSV infection. First, we assumed that antibody levels
in the mother would exponentially increase from 7 days post-
vaccination and reach a maximal level at 21 days post-
vaccination. This level was assumed to stay constant through
the rest of pregnancy [15]. If, however, antibody levels in the
mother actually declined over time, antibody transfer to the foe-
tus would be reduced and our model would overestimate the per-
centage of cases prevented by maternal vaccination. Additionally,
if maternal antibody levels were to decline over time, this couldaffect the optimal timing of maternal vaccination. Second, our
model did not consider reduced transplacental transfer caused
by maternal comorbidities, such as malaria or hypergammaglob-
ulinemia [12]. Third, in our model for maternal vaccine-induced
antibody dynamics, we assumed that the antibody half-life was
41 days, based on available maternal RSV vaccine phase-2 trial
data [21], which is higher than reported by others [37]. When
we considered an antibody half-life as short as 20 days, the per-
centage of prevented cases would be reduced (e.g. 11–24%
instead of 35–56% of RSV-related in-hospital deaths for maternal
vaccination at 30 weeks’ GA). Fourth, we assumed full protection
from life-threatening RSV infection as long as a child’s predicted
antibody levels remained above the protective threshold of 40
lg/ml [24,29,30]. However, the correlation between antibody
levels and protection from RSV disease has not been well defined
[15,38,39]. Fifth, our results describe the situation in which all
mothers would have been vaccinated during pregnancy. When
we considered a vaccine coverage of 60%, based on the observed
vaccine coverage for maternal pertussis vaccination in the United
Kingdom and Belgium [40,41], the percentage of prevented cases
would be substantially lower (e.g. 42–48% and 50–54% instead of
62–75% and 76–87% of RSV-related PICU admissions in the United
Kingdom and the Netherlands respectively for maternal vaccina-
tion at 30 weeks’ GA). Finally, protection from RSV infection
was assumed to result in prevention of RSV-related PICU admis-
sion or death, whereas for some children it may merely have
postponed these RSV-related outcomes.
In summary, our mathematical model suggests that maternal
vaccination against RSV could substantially decrease the number
of life-threatening RSV infections in infants. In order to inform pol-
icy makers about the need for additional preventive interventions
after birth for high-risk groups, such as preterm children, future
studies on maternal vaccination should provide accurate data for
transplacental antibody transfer per week of gestation, antibody
half-life in new-born children and the protective antibody
threshold.Conflict of interest
All authors declare no conflict of interests.Appendix A. Supplementary material
Supplementary data associated with this article can be found, in
the online version, at https://doi.org/10.1016/j.vaccine.2018.06.
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